Business Wire

SAMANTREE-MEDICAL

16.7.2024 07:01:34 CEST | Business Wire | Press release

Share
SamanTree Medical Raises $14M in Series B Financing Round to Support Global Expansion and Innovation in Surgical Treatment

SamanTree Medical, a leading medical technology company specializing in innovative solutions to improve the outcomes of surgery, today announced the closing of $14M as part of a Series B financing round. The new capital will be used to further develop and commercialize the Histolog® Scanner, expand its reach in Europe and the United States, and enhance its digital suite.

Revolutionizing Surgery with the Histolog® Scanner

The Histolog Scanner, a CE-marked device, allows for high-resolution imaging of fresh tissue surfaces during surgery, enabling pathologists and surgeons to perform real-time intra-operative assessment of resected tissue much faster than the conventional techniques. This innovative technology is based on ultra-fast confocal microscopy.

Investment

The round was led by Relyens Innovation Santé, advised by Turenne Capital, and saw participation from new investors Mutuelles Impact, Wille Finance, Noshaq and WE Life Sciences (Wallonie Entreprendre), along with returning investors Panakès Partners, BOM and b2venture. In conjunction with this financing round, SamanTree Medical will establish its headquarters and an operational base in Wallonia (Belgium), while the R&D operations will remain in Lausanne, Switzerland. Fraser Partners acted as sole financial advisor to SamanTree Medical SA.

Board of Directors Update

Joining the Board of Directors are Claire Poulard, Investment Director at Turenne Capital, and Henry Charlton, SVP and Chief Commercial & Marketing Officer at Intuitive. The new Board composition is as follows:

  • Fabrizio Landi
  • Claire Poulard
  • Henry Charlton
  • Dr. Charles Carignan (Chairman)
  • Olivier Delporte (CEO)

CEO Olivier Delporte explained: “We are elated by the robust support from our investors, which highlights SamanTree Medical's impressive progress. This funding, coupled with our strengthened Board, will enable us to accelerate our innovation, expand globally, and enhance our digital solutions, thereby delivering greater value to patients. I also want to thank the Walloon investors WE Life Sciences and Noshaq for their continuing support and effort to strengthen the local life sciences ecosystem.”

“SamanTree Medical has demonstrated that the Histolog® Scanner can provide real-time, high-resolution imaging during surgery, and it has the potential to improve surgical outcomes. We are impressed with the company's performance and the clinical data supporting the use of the Histolog® Scanner in multiple soft-tissue surgical procedures. We look forward to partnering with SamanTree Medical to bring this transformative technology to more patients worldwide,” said Claire Poulard, Investment Director at Turenne Capital.

“I am excited to join the Board of SamanTree Medical at such a pivotal time for the company. The Histolog Scanner is a potentially significant advancement that provides surgeons with real-time actionable information to their decision-making,” said Henry Charlton, SVP and Chief Commercial Officer at Intuitive.

Strategic Vision and Global Expansion

As part of the financing conditions, SamanTree Medical is set to expand its commercial operations in Europe and is planning for US market entry later in 2024. This strategic move will involve scaling the deployment of the Histolog Scanner, bolstering clinical trials, and working to obtain necessary marketing authorizations from the U.S. FDA.

About SamanTree Medical and the Histolog Scanner

SamanTree Medical is dedicated to improving outcomes for patients undergoing surgery through innovative medical imaging solutions. The company has developed the Histolog Scanner, a novel device that offers real-time, high-resolution fresh tissue surface imaging during surgical procedures, that may significantly enhance the accuracy of tissue removal or biopsy. The Histolog Scanner covers a broad range of surgical applications in surgery and is currently commercialized in Europe. It is an investigational device in the US.

For more information, visit www.samantree.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240715376136/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Align Partners Issues Formal Shareholder Proposals to Gabia13.2.2026 01:37:00 CET | Press release

Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Gabia, Inc. (“Gabia” or the “Company”), has submitted formal shareholder proposals for inclusion in the agenda of Gabia’s upcoming 27th Annual General Meeting (“AGM”) and issued a call for strengthened governance practices to address the Company’s persistent undervaluation. Align Partners noted that, as shareholder proposals will be presented at this year’s AGM, Gabia should follow the Korea Exchange (KRX) Corporate Governance Key Indicators by publishing the AGM convocation notice at least four weeks prior to the meeting date. Align Partners emphasized that last year’s AGM notice was issued only 16 days before the meeting, limiting shareholders’ ability to adequately review the agenda and exercise informed voting rights. Gabia is widely recognized as a leading Korean IT services and cloud infrastructure company with solid operating performance. Despite these strengths, Align Partners believes the Company conti

Andersen Consulting udvider sin platform i Nordamerika med tilføjelsen af Kezber12.2.2026 22:50:00 CET | Pressemeddelelse

Andersen Consulting styrker sine ydelser inden for forretningstransformation og cybersikkerhed med tilføjelsen af den canadisk-baserede samarbejdsvirksomhed Kezber. Kezber blev stiftet i 1996 og specialiserer sig i at levere en komplet pakke af it-løsninger, herunder managed it-services, infrastruktursupport, cybersikkerhed, cloudtjenester, specialudviklet software, business intelligence og ai-tjenester samt automatisering af forretningsprocesser. Firmaet samarbejder med organisationer med henblij på at øge produktiviteten, modernisere deres teknologiske miljøer og udnytte datadrevne løsninger til at nå strategiske mål. "Vores samarbejde med Andersen Consulting giver os mulighed for at inddrage hele vores pakke af software og it-tjenester i en bredere konsulentramme," udtaler Alan Kezber, administrerende direktør for Kezber. "Ved at integrere vores tekniske ekspertise med Andersen Consultings omfattende konsulentkompetencer kan vi tilbyde kunderne løsninger, der skaber driftsforbedring

Europe Launches Euro-Q-Exa Quantum Computer in Germany, Strengthening Sovereign Digital Infrastructure12.2.2026 21:15:00 CET | Press release

Euro-Q-Exa will serve the scientific community and industry across Germany and Europe, enabling hands-on quantum research and application development within Europe’s HPC ecosystem. Installed, hosted, and operated at Leibniz Supercomputing Centre (LRZ), ensuring local control, operational expertise, and long-term capability building. Developed by IQM Quantum Computers using its Radiance platform, designed to enable institutions to build, operate, and evolve their own quantum capability. Engineered for deep integration with high-performance computing, supporting scalable hybrid quantum–HPC workflows. Co-funded by the EuroHPC Joint Undertaking, the German Federal Ministry of Research, Technology and Space (BMFTR), and the Bavarian State Ministry of Science and the Arts (StWK). Euro-Q-Exa, the first EuroHPC Joint Undertaking quantum computer deployed in Germany, has been unveiled at the Leibniz Supercomputing Centre (LRZ) in Garching, Munich. This press release features multimedia. View th

Sindre Zeiner-Gundersen Joins Joi Scientific12.2.2026 20:00:00 CET | Press release

Joi Scientific is pleased to welcome Sindre Zeiner-Gundersen as the company’s Advanced Plasma & Resonant Energy Physicist. Sindre will lead Joi’s scientific activities including all aspects of Joi’s science program. Sindre is a quantum physics expert who previously served as CEO/President of Nornec AS, a Norwegian consulting and engineering services company. Nornec has been a consultant to Joi since 2024. At Nornec, Sindre provided consulting and R&D services in the areas of advanced nuclear reactor simulations, process and plant optimization, carbon capture optimization, materials selection and radiation effects, custom reactor design, muon and neutron detector systems, muon and catalyzed fusion and Hydrogen Rydberg Matter research. An applied physicist with end‑to‑end expertise in energy‑carrier gases - ammonia, methanol, hydrogen - as well as a radiation instrumentation specialist with experience in process and equipment design across the ammonia/hydrogen value chain, Sindre has aut

Angelalign Technology Inc. (6699.HK) Says a Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on Users12.2.2026 17:58:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel”) said a ruling by the Unified Patent Court of Düsseldorf, Germany that it preliminarily cease its use of certain software functions that automatically update treatment plans would have minimal impact on the orthodontists and patients who use its clear aligner products. The ruling applies to certain European countries and excludes Spain, Switzerland, United Kingdom and Ireland. Angel will launch iPlan for applicable European users, which is an upgrade feature that has the same reliability and more flexibility for users. Angel denies that the Live Now feature in its iOrtho treatment planning software infringes any valid patents of Align Technology Inc. (ALGN). Angel has already filed an opposition against the patent with the European Patent Office (EPO), arguing that the claimed invention is neither novel nor inventive over the prior art, and is seeking its permanent invalidation. Angel is confident it will overcome the first-instance, non-fi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye